Gilead Sciences (BSP:GILD34) Marketable Securities : R$0 Mil (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Gilead Sciences Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Gilead Sciences's Marketable Securities for the quarter that ended in Mar. 2024 was R$0 Mil.

Gilead Sciences's annual Marketable Securities declined from Dec. 2021 (R$6,684 Mil) to Dec. 2022 (R$5,104 Mil) but then increased from Dec. 2022 (R$5,104 Mil) to Dec. 2023 (R$5,777 Mil).

Gilead Sciences Marketable Securities Historical Data

The historical data trend for Gilead Sciences's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Marketable Securities Chart

Gilead Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Marketable Securities

Get a 7-Day Free Trial

52,213.35

7,259.17

6,684.09

5,103.77

5,776.86

Gilead Sciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Marketable Securities	Get a 7-Day Free Trial															4,875.25	4,674.11	5,723.95	5,776.86	-

Gilead Sciences Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Gilead Sciences (BSP:GILD34) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Gilead Sciences Marketable Securities Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Gilead Sciences (BSP:GILD34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (BSP:GILD34) » Definitions » Marketable Securities

Comparable Companies

Traded in Other Exchanges

GILD:USA GILD:Mexico GILD:Italy GISd:UK 0QYQ:UK GIS:Germany GILD:Austria GILD:Argentina

Address

333 Lakeside Drive, Foster, CA, USA, 94404

Website

https://www.gilead.com

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Gilead Sciences (BSP:GILD34) Headlines

No Headlines